Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental radioimmunotherapy

D J Buchsbaum1, V K Langmuir, B W Wessels

  • 1Department of Radiation Oncology, University of Alabama, Birmigham 35233.

Medical Physics
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Excitons in CsPbBr<sub>3</sub> Halide Perovskite.

The journal of physical chemistry letters·2021
Same author

Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.

Cancer gene therapy·2014
Same author

Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling.

Oncogene·2013
Same author

Molecular targeted approaches for treatment of pancreatic cancer.

Current pharmaceutical design·2011
Same author

Magnetoamplification in a bipolar magnetic junction transistor.

Physical review letters·2010
Same author

A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.

Cancer chemotherapy and pharmacology·2010
Same journal

Correction to "On the shape of the radiation survival curve in tumor spheroids: The role of oxygen heterogeneity".

Medical physics·2026
Same journal

Multi-view constrained semi-supervised vertebra detection for 3D ultrasound spine volume.

Medical physics·2026
Same journal

Accuracy of quantitative <sup>177</sup>Lu SPECT/CT imaging: A systematic review.

Medical physics·2026
Same journal

Physics-constrained dual-domain network for CBCT reconstruction from orthogonal X-rays in gynecologic radiotherapy.

Medical physics·2026
Same journal

Decomposition-based harmonization for quantitative PET imaging across scanners and radiotracers.

Medical physics·2026
Same journal

Development and evaluation of an in vivo dose-based monitoring system for electron FLASH radiation therapy.

Medical physics·2026
See all related articles

Radioimmunotherapy using radiolabeled monoclonal antibodies shows promise for treating various cancers. Effective treatment relies on antibody penetration and radionuclide half-life, with studies demonstrating significant cell kill in tumor models.

Area of Science:

  • Nuclear medicine
  • Oncology
  • Immunotherapy

Background:

  • Radiolabeled monoclonal antibodies (mAbs) are utilized in radioimmunotherapy (RIT) for cancer treatment.
  • Previous studies have explored RIT in human tumor spheroids and animal xenograft models.
  • This review synthesizes RIT research, focusing on dosimetry and correlation of findings in preclinical models.

Purpose of the Study:

  • To review radioimmunotherapy studies conducted in human tumor spheroids and animal xenograft models.
  • To highlight studies that provide dosimetry estimates and correlate RIT findings.
  • To discuss factors influencing the efficacy of radiolabeled mAb therapy.

Main Methods:

  • Review of published radioimmunotherapy studies using various cancer models (spheroids and xenografts).

Related Experiment Videos

  • Analysis of studies employing different radiolabeled antibodies (e.g., 131I, 186Re, 212Bi, 90Y).
  • Examination of dosimetry estimation methods, including MIRD, thermoluminescent dosimetry, and autoradiography.

    • Main Results:

    • In spheroid models, up to three logs of cell kill were achieved with 131I- and 186Re-labeled antibodies.
    • Therapeutic efficacy in spheroids depends on antibody penetration and adequate radionuclide half-life.
    • Tumor doses in animal models ranged from 17 to 11,171 mGy/MBq, with various radionuclides showing efficacy.

    Conclusions:

    • Radioimmunotherapy demonstrates potential in preclinical cancer models.
    • Key factors for successful RIT include antibody characteristics (specificity, affinity) and tumor-related factors (antigen expression, vascularity).
    • Further optimization of radiolabeled mAb strategies is warranted for clinical translation.